IM Cannabis Corp. reported its financial results for the fourth quarter and full year of 2024, highlighting a 25% increase in revenue for Q4 2024 compared to the same period in 2023, and an 11% annual revenue growth. The company achieved a significant reduction in operating expenses by 42% in Q4 2024 and 17% annually, resulting in an adjusted EBITDA profit of $0.5 million in the fourth quarter, a notable improvement from a loss of $4.3 million in the same quarter of the previous year. The growth in revenue was primarily driven by an 183% increase in the German market, reaching $15.5 million in 2024 compared to $5.5 million in 2023. This performance was attributed to strategic and operational improvements throughout the year. Despite a decrease in revenue in Israel due to the cancellation of the Oranim deal, the company managed to decrease its annual adjusted EBITDA loss by 87% from $8.0 million in 2023 to $1.1 million in 2024. IM Cannabis Corp. also announced plans to host a conference call to discuss these results, indicating a focus on transparency and communication with investors. The company's management expressed optimism about the future, anticipating that the first quarter of 2025 would be the best in sales to date in Germany.